Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
1.620
+0.090 (5.88%)
At close: Mar 9, 2026, 4:00 PM EDT
1.574
-0.046 (-2.86%)
After-hours: Mar 9, 2026, 4:19 PM EDT
Geron Market Cap
Geron has a market cap or net worth of $1.04 billion as of March 9, 2026. Its market cap has decreased by -34.73% in one year.
Market Cap
1.04B
Enterprise Value
744.45M
1-Year Change
-34.73%
Ranking
Category
Stock Price
$1.62
Market Cap Chart
Since December 1, 1998, Geron's market cap has increased from $159.40M to $1.04B, an increase of 550.99%. That is a compound annual growth rate of 7.11%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 980.00M | 16.31% |
| Dec 31, 2025 | 842.60M | -60.62% |
| Dec 31, 2024 | 2.14B | 86.74% |
| Dec 29, 2023 | 1.15B | 24.20% |
| Dec 30, 2022 | 922.60M | 134.88% |
| Dec 31, 2021 | 392.80M | -20.44% |
| Dec 31, 2020 | 493.70M | 81.71% |
| Dec 31, 2019 | 271.70M | 45.84% |
| Dec 31, 2018 | 186.30M | -35.00% |
| Dec 29, 2017 | 286.60M | -12.99% |
| Dec 30, 2016 | 329.40M | -56.99% |
| Dec 31, 2015 | 765.80M | 49.89% |
| Dec 31, 2014 | 510.90M | -16.42% |
| Dec 31, 2013 | 611.30M | 231.51% |
| Dec 31, 2012 | 184.40M | -5.24% |
| Dec 30, 2011 | 194.60M | -63.43% |
| Dec 31, 2010 | 532.20M | 4.66% |
| Dec 31, 2009 | 508.50M | 37.54% |
| Dec 31, 2008 | 369.70M | -13.62% |
| Dec 31, 2007 | 428.00M | -26.52% |
| Dec 29, 2006 | 582.50M | 4.37% |
| Dec 30, 2005 | 558.10M | 53.45% |
| Dec 31, 2004 | 363.70M | -6.72% |
| Dec 31, 2003 | 389.90M | 337.60% |
| Dec 31, 2002 | 89.10M | -53.52% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AbCellera Biologics | 1.05B |
| ArriVent BioPharma | 1.04B |
| Inhibrx Biosciences | 1.01B |
| Xeris Biopharma Holdings | 1.00B |
| UroGen Pharma | 996.04M |
| Compass Therapeutics | 992.28M |
| GH Research | 988.13M |
| Aktis Oncology | 987.94M |